Ideal Generic Pathway for patients with suspected Acute Myeloid Leukaemia (AML) & Acute Lymphocytic Leukaemia (ALL)

2WW Referral received for suspected leukaemia
Young and fit older patients able to tolerate intensive chemotherapy are referred directly to Leeds

- Haematologist consultation
  - Physical examination
  - Blood test
  - Imaging

Are results suggestive of leukaemia?

- Yes
  - Discuss results with patient
  - Bone Marrow undertaken
  - Treatment may need to commence before MDT discussion
  - Specialist MDT review of results, plan treatment and consider suitability for clinical trials
  - Discuss results with patient and agree treatment options
  - Chemotherapy
  - Supportive Palliative Care
  - Long term monitoring of disease

- No
  - Manage as appropriate and remove from cancer pathway

16-18 years old – refer to Paediatric Oncology (GNCC) for treatment and TYA MDT for discussion.
19-24 years old – continue on tumour site specific pathway & refer to TYA MDT for discussion.

- Taxonomy: Medical Condition - Leukemia
- Alberton Pathway: Acute Myeloid & Lymphocytic Leukaemia (AML & ALL)
- Date: April 2019
- Inter Provider Transfer Network Best Practice
- Decision to Treat
- Consider referral to specialist fertility services
- First Treatment
- Maximum wait (days)
- First Seen
- Provide information and appropriate level of psychological support throughout the patient journey
- See TYA pathway
- Holistic assessment and rehabilitation consideration
- Liaise and involve healthcare professionals as required
- Electronic Cancer Assessment and Delivery (ECAD)